Marc Schwabish leads BD and US Operations at Fusion Pharmaceuticals. Fusion is developing radiotherapeutics with its proprietary Fast-ClearTM Linker Technology and was spun-out of a radiopharmaceutical manufacturer in 2017 with a $46M Series A. Dr. Schwabish’s background spans across Biopharma, Finance, Consulting, and Science. He was previously Head of US Pharma BD&L at Bayer and at Eisai, had both BD and Alliance Management responsibilities. Marc worked in Healthcare Investment Banking, Pharma Strategy Consulting, and other Pharma/Biotech companies. Dr. Schwabish holds a Ph.D. in Biochemistry and Molecular Pharmacology from Harvard and a B.S. in Biology from Cornell.